SCHEMBL3473161

SCHEMBL3473161

O=C(O)CCC(=O)OC1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 2/20 0.56
LMNA P02545 3/20 0.53
CYP2C19 P33261 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.45
HTT P42858 1/20 0.44
ALDH1A1 P00352 3/20 0.43
CYP19A1 P11511 2/20 0.43
MMP3 P08254 2/20 0.41
EPHX1 P07099 2/20 0.41
EGLN1 Q9GZT9 2/20 0.39
ALKBH5 Q6P6C2 1/20 0.39
SUCNR1 Q9BXA5 1/20 0.39
KDM6B O15054 1/20 0.39
KDM5C P41229 1/20 0.39
PHF8 Q9UPP1 1/20 0.39
KDM2A Q9Y2K7 1/20 0.39
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
THRA P10827 1/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyclohexane SCHEMBL27646533 0.98 NAAA (0.58) NAAALMNACYP2C19SMN1; SMN2HTT
SCHEMBL22213807 0.98 NAAA (0.58) NAAALMNACYP2C19SMN1; SMN2HTT
SCHEMBL3472508 0.98 NAAA (0.58) NAAALMNACYP2C19SMN1; SMN2HTT
SCHEMBL27617118 0.96 NAAA (0.52) NAAALMNACYP2C19SMN1; SMN2HTT
SCHEMBL19690549 0.91 LMNA (0.47) NAAALMNACYP2C19SMN1; SMN2HTT
SCHEMBL5071456 0.91 LMNA (0.47) NAAALMNACYP2C19SMN1; SMN2HTT
SCHEMBL207015 0.91 NAAA (0.64) NAAALMNACYP2C19SMN1; SMN2HTT
Butane SCHEMBL2857848 0.91 NAAA (0.65) NAAALMNACYP2C19SMN1; SMN2HTT
SCHEMBL258780 0.89 NAAA (0.66) NAAALMNACYP2C19SMN1; SMN2HTT
SCHEMBL7568980 0.89 NAAA (0.66) NAAALMNACYP2C19SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456278-B2 Lactams substituted by cyclic succinates as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) 2008-11-25 US claimed
US-20080103128-A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-05-01 US claimed
US-20250154181-A1 TREPROSTINIL PRODRUGS UNITED THERAPEUTICS CORPORATION (US) 2025-05-15 US disclosed
US-12173021-B2 Treprostinil prodrugs UNITED THERAPEUTICS CORPORATION (US) 2024-12-24 US disclosed
US-20240051979-A1 TREPROSTINIL PRODRUGS UNITED THERAPEUTICS CORPORATION (US) 2024-02-15 US disclosed
US-11634443-B2 Treprostinil prodrugs UNITED THERAPEUTICS CORPORATION (US) 2023-04-25 US disclosed
CN-114616225-A Treprostinil prodrugs 联合治疗公司 2022-06-10 CN disclosed
US-8586731-B2 Hydrophobic polysaccharides with diester- or carbonate ester-containing linkages having enhanced degradation SURMODICS, INC. (US) 2013-11-19 US disclosed
CN-102712705-A Preparation method of solid catalyst for propylene polymerization SAMSUNG TOTAL PETROCHEMICALS 2012-10-03 CN disclosed
US-20100316687-A1 HYDROPHOBIC POLYSACCHARIDES WITH DIESTER- OR CARBONATE ESTER-CONTAINING LINKAGES HAVING ENHANCED DEGRADATION SURMODICS MD, LLC 2010-12-16 US disclosed
CN-101189295-B Cellulose ester film, polarizing plate and liquid crystal display KONICA MINOLTA OPTO INC 2010-12-15 CN disclosed
US-7354914-B2 Lactams substituted by cyclic succinates as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-04-08 US disclosed
US-20050261274-A1 Lactams substituted by cyclic succinates as inhibitors of Abeta protein production OLSON RICHARD E 2005-11-24 US disclosed
US-6958329-B2 Lactams substituted by cyclic succinates as inhibitors of A-β protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-10-25 US disclosed
US-20030119815-A1 Lactams substituted by cyclic succinates as inhibitors of A-beta protein production OLSON RICHARD E (US) 2003-06-26 US disclosed
US-6509333-B2 Lactams substituted by cyclic succinates as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-01-21 US disclosed
EP-1268450-A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2003-01-02 EP disclosed
CN-1386118-A Lactams substituted by cyclic succinates as inhibitors of A beta protein production BRISTOL MYERS SQUIBB CO (US) 2002-12-18 CN disclosed
US-20020137737-A1 Lactams substituted by cyclic succinates as inhibitors of a beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-09-26 US disclosed
WO-2001092235-A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154181-A1 TREPROSTINIL PRODRUGS TYMP, TK1, DCTPP1 NAAA 178/4885LMNA 3503/4885CYP2C19 44/4885
US-20020137737-A1 Lactams substituted by cyclic succinates as inhibitors of a beta protein production APP, BACE1, APH1A NAAA 264/4885LMNA 1628/4885CYP2C19 1406/4885
US-20050261274-A1 Lactams substituted by cyclic succinates as inhibitors of Abeta protein production BACE1, APP, APH1A NAAA 690/4885LMNA 1656/4885CYP2C19 1601/4885
US-20080103128-A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION APH1A, APH1B, APP NAAA 119/4885LMNA 2433/4885CYP2C19 1438/4885
US-20240051979-A1 TREPROSTINIL PRODRUGS TYMP, TK1, DCTPP1 NAAA 178/4885LMNA 3503/4885CYP2C19 44/4885
US-20030119815-A1 Lactams substituted by cyclic succinates as inhibitors of A-beta protein production APH1A, APH1B, APP NAAA 143/4885LMNA 1505/4885CYP2C19 1537/4885
US-20100316687-A1 HYDROPHOBIC POLYSACCHARIDES WITH DIESTER- OR CARBONATE ESTER-CONTAINING LINKAGES HAVING ENHANCED DEGRADATION CD44, SI, ENGASE NAAA 1210/4885LMNA 1409/4885CYP2C19 876/4885
US-12173021-B2 Treprostinil prodrugs TYMP, TK1, DCTPP1 NAAA 178/4885LMNA 3503/4885CYP2C19 44/4885
US-11634443-B2 Treprostinil prodrugs TYMP, TK1, DCTPP1 NAAA 178/4885LMNA 3503/4885CYP2C19 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.